I期和II期非小细胞肺癌的管理
本文综述I期和II期非小细胞肺癌的管理策略。可手术且心肺风险低的患者,肺叶切除加完全手术切除仍是金标准;微创、保守和亚肺叶切除适用于部分患者。立体定向体部放疗是手术高风险患者的有效替代,但在良好手术候选者中仍需随机试验评估;特定亚组辅助化疗可延长生存,新辅助化疗可能类似;靶向和免疫治疗的作用尚未确定,等待随机试验结果。
要点
- 可手术且心肺风险低的I-II期NSCLC,肺叶切除加完全手术切除是金标准。
- 微创、保守和亚肺叶切除适用于部分患者。
- 立体定向体部放疗是手术高风险患者的有效替代,良好手术候选者需随机试验评估。
核心结论
- I期和II期NSCLC管理需多学科协作,局部治疗包括手术和放疗,特定病例联合(新)辅助化疗以改善长期结局。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 可手术且心肺风险低的患者,肺叶切除加完全手术切除仍是金标准。
- 微创技术、保守和亚肺叶切除适用于部分患者。
- 立体定向体部放疗是手术高风险患者的有效替代,但在良好手术候选者中需随机试验评估。
- 特定亚组辅助化疗可延长生存,患者选择重要;新辅助化疗可能产生与辅助化疗相似的结果。
- 靶向治疗和免疫治疗在早期NSCLC中的作用尚未确定,等待随机试验结果。
临床怎么用
- 可手术且心肺风险低的I-II期NSCLC患者,优先考虑肺叶切除加完全手术切除。
- 手术高风险患者可考虑立体定向体部放疗作为替代。
- 特定亚组患者可考虑辅助化疗以延长生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard. Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients. Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery. Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important. Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.
引用
- McDonald F, De Waele M, Hendriks LE, et al. Management of stage I and II nonsmall cell lung cancer. Eur Respir J. 2017. PMID: 28049169. doi:10.1183/13993003.00764-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。